Viventia's Cancer Ambitions Go To Eleven
Executive Summary
Merger with troubled ophthalmology biotech Eleven takes Viventia public and joins the protein-engineering and manufacturing expertise of the two firms. Lead candidate Vicinium is in Phase III for high-grade, non-muscle invasive bladder cancer.
You may also be interested in...
Report: Women Eschew Life Science Companies That Lack Female Leadership
MassBio and Liftstream partnered on a report about women's, men's and companies' views on gender diversity in the life science industry and identified several opportunities for employers to improve, including the need to employ more women in leadership roles to attract female job-seekers.
J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
Plunging biopharma company stock values and declining IPO activity have contributed to a more difficult financing environment, but money is still available for public and private drug developers whose products provide value in the eyes of patients and payers.